

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY CIRCULATION BY THE BOARD OF DIRECTORS OF EMCURE PHARMACEUTICALS LIMITED ON MARCH 18, 2024.

APPROVAL AND ADOPTION OF THE ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS IN RELATION TO THE INITIAL PUBLIC OFFER:

“RESOLVED THAT in furtherance of the resolutions adopted by the Board on December 15, 2023 and by the IPO Committee dated December 16, 2023 approving the Draft Red Herring Prospectus dated December 16, 2023 (“DRHP”), filed with the Securities and Exchange Board of India (“SEBI”) and with the BSE Limited & the National Stock Exchange of India Limited (“Stock Exchanges”), where the equity shares of the Company are proposed to be listed, and in succession to the resolution by circulation passed by the Board on March 18, 2024, identifying Mrs. Namita Vikas Thapar and Mr. Samit Satish Mehta as “Promoters” along with Mr. Satish Ramanlal Mehta and Mr. Sunil Rajanikant Mehta, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), the Companies Act, 2013 read with the Rules made thereunder, each as amended, the addendum to the DRHP, dated March 18, 2024, (“Addendum”) having certain updates to the relevant sections of the DRHP, in relation to the Promoters and the Promoter Group of the Company, subject to it being duly signed by the Directors of the Company, the Chief Financial Officer of the Company and the Selling Shareholders (or their duly authorised representatives), as provided to and placed before the Board, be and is hereby approved and adopted for dissemination to public by way of a public announcement in the newspapers and for filing with the SEBI, Stock Exchanges and other relevant authorities or persons, as required.

RESOLVED FURTHER THAT any Director or the Key Managerial Personnel of the Company, be and are hereby severally authorized to finalise the Addendum and file the same with SEBI, the Stock Exchanges and such other authorities or persons as may be required, issue public announcements in the newspapers and such certificates and confirmations as may be required and undertake such other necessary acts, things and deeds on behalf of the Company, to implement this resolution.

RESOLVED FURTHER THAT the IPO Committee be and is hereby authorized to undertake, approve and adopt any subsequent changes, correction, updates, alterations, revisions, modifications or amendments, if any, and to finalise the Addendum for the purposes of dissemination to public by way of a public announcement in the newspapers and



Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** U24231PN1981PLC024251

for filing with the SEBI, the Stock Exchanges and such other authorities or persons as may be required, and issue such certificates and confirmations as may be required and do all acts, deeds, matters and undertake such other necessary steps to implement this resolution, including without limitation, to settle any questions, difficulties or doubts that may arise in relation thereto.

RESOLVED FURTHER THAT any Director and Key Managerial Personnel of the Company, be and are hereby severally authorized to issue certified true copies of this resolution as may be required from time to time."

//CERTIFIED TO BE TRUE//

For EMCURE PHARMACEUTICALS LIMITED



CHETAN SHARMA
COMPANY SECRETARY

MEMBERSHIP NO: F8352

ADDRESS: PLOT NO. P-1 & P-2,
IT-BT PARK, PHASE-II, M.I.D.C,
HINJAWADI, PUNE - 411057

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** U24231PN1981PLC024251